vimarsana.com
Home
Live Updates
Horizon Therapeutics plc Announces FDA Approval of an Update
Horizon Therapeutics plc Announces FDA Approval of an Update
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration
-- Updated indication language reinforces the importance of unrestricted access for patients across full spectrum of Thyroid Eye Disease --
... | April 14, 2023
Related Keywords
United States ,
Tim Walbert ,
Drug Administration ,
Facebook ,
Nasdaq ,
European Group On Grave ,
Instagram ,
European Group On Grave Orbitopathy ,
Linkedin ,
Visa ,
Twitter ,
Exchange Commission ,
Horizon Therapeutics ,
Eye Disease ,
Thyroid Eye Disease ,
Thyroid Eye ,
Inflammatory Bowel Disease ,
Full Prescribing Information ,
United States Securities ,
Thyroid Associated ,
Grave Disease Is Mediated Through ,
Insulin Like Growth Factor ,
European Group ,
Grave Orbitopathy ,
Horizon Therapeutics Public Limited Company Stock Exchange ,
News ,
Information ,
Press Release ,
Pdated ,
Indication ,
Language ,
Reinforces ,
The ,
Importance ,
F ,
Unrestricted ,
Access ,
Or ,
Patients ,
Cross ,
Bull ,
Spectrum ,
Thyroid ,
Eye ,
Isease Hznp Ie00bqpvqz61 ,